Literature DB >> 11850763

Fixed dose combination therapy in the treatment of hypertension.

T Stanton1, J L Reid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850763     DOI： 10.1038/sj.jhh.1001312

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN： 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  7 in total

Review 1.  Combination therapy as first-line treatment for hypertension.

Authors:  Irene Gavras; Talma Rosenthal
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

2.  Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study).

Authors:  Marjorie Gatlin; Wentworth G Jarrett; Oliseyenum M Nwose
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

3.  Nebivolol/Hydrochlorothiazide : a new fixed-dose combination for effective simplified antihypertensive therapy.

Authors:  Ettore Malacco
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

4.  Prediction of drug combinations by integrating molecular and pharmacological data.

Authors:  Xing-Ming Zhao; Murat Iskar; Georg Zeller; Michael Kuhn; Vera van Noort; Peer Bork
Journal:  PLoS Comput Biol       Date:  2011-12-29       Impact factor: 4.475

5.  A study of use of fixed dose combinations in Ahmedabad, India.

Authors:  Jayeshbhai Dineshchandra Balat; Anuradha M Gandhi; Prakruti P Patel; Ram K Dikshit
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200

6.  A multicenter cohort study of primary hypertension in Korea: study design and interim analysis of the Korean registry of target organ damage in hypertension (KorHR).

Authors:  Suk-Won Choi; Seong Woo Han; Jong Sun Ok; Byung-Su Yoo; Mi-Seung Shin; Sung Ha Park; Kyu-Hyung Ryu
Journal:  Clin Hypertens       Date:  2017-08-02

7.  Drug target optimization in chronic myeloid leukemia using innovative computational platform.

Authors:  Ryan Chuang; Benjamin A Hall; David Benque; Byron Cook; Samin Ishtiaq; Nir Piterman; Alex Taylor; Moshe Vardi; Steffen Koschmieder; Berthold Gottgens; Jasmin Fisher
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.